Phase 2 N=81 Clofarabine Plus Low-Dose Cytarabine for Patients With Higher-Risk Myelodysplastic Syndrome (MDS)
Leukemia · Myeloproliferative Diseases
Primary: Number of Participants With Complete Response (CR) — 19 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=77 Obeticholic Acid (OCA) in Primary Sclerosing Cholangitis (PSC)
Primary Sclerosing Cholangitis (PSC)
Primary: DB Phase: Change From Baseline In Serum Alkaline Phosphatase (ALP) — -105.05; -110.19; -26.76 U/L — p=0.0434
Phase 2 N=36 Omacetaxine and Low Dose Cytarabine in Older Patients With Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)
Leukemia
Primary: Percentage of Participants With Complete Remission (CR) — 44 percentage of participants
Phase 2 N=65 Safety and Efficacy Study of M2951 in Participants With Rheumatoid Arthritis
Rheumatoid Arthritis
Primary: Proportion of Participants Who Achieved American College of Rheumatology-20 (ACR20) Response — 0.42; 0.52 proportion of participants
Phase 2 N=364 A Study Of PF-06463922 An ALK/ROS1 Inhibitor In Patients With Advanced Non Small Cell Lung Cancer With Specific Molecular Alterations
ALK-positive Non Small Cell Lung Cancer (NSCLC) and ROS1-positive NSCLC
Primary: Number of Participants With Cycle 1 Dose-Limiting Toxicities (DLTs) in Phase 1 — 0; 0; 0; 0 Participants
Phase 2 N=74 Phase II Trial of Nab-Paclitaxel and Gemcitabine for First-Line Treatment of Patients With Cholangiocarcinoma
Cholangiocarcinoma
Primary: Progression-Free Survival (PFS) Rate at 6 Months (Proportion of Participants Alive and Progression-Free at 6 Months) — 0.605 proportion of participants
Phase 2 N=17 Prolonged Exposure and Oxytocin
PTSD
Primary: PTSD Symptom Severity — 13.00; 17.71 scores on a scale
Phase 2 N=137 Comparative Study of NXL104/Ceftazidime Versus Comparator in Adults With Complicated Urinary Tract Infections
Complicated Urinary Tract Infection
Primary: Number of Participants With Microbiological Outcome at the Test of Cure (TOC) Visit — 19; 25 Participants
Phase 2 N=38 Trial of Dasatinib (Sprycel®) in Subjects With Hormone-refractory Prostate Cancer
Hormone-refractory Prostate Cancer · Adenocarcinoma of the Prostate · Hormone-resistant Prostate Cancer
Primary: Number of Subjects With Disease Control (DC) (Based on PSA, Bone Scan, FACT-P, RECIST) — 5 Participants
Phase 2 N=71 Functional Neuroimaging of Alcoholism Vulnerability (PIT)
Healthy
Primary: Change in Blood Oxygenation Level Dependent (BOLD) Activation in the Amygdala During "Win" Monetary Incentive Delay (MID) Task Between Placebo and Study Medication…
Phase 2 N=90 Evaluation of Metformin, Targeting Cancer Stem Cells for Prevention of Relapse in Gynecologic Patients
Ovarian, Fallopian Tube, and Primary Peritoneal Cancer
Primary: Recurrence-Free Survival — 58.1; 55.6 percentage of patients
Phase 2 N=20 Effect of Background Noise on Sleep Quality
Sleep Onset Insomnia
Primary: Sleep Onset Latency (Mins) — 13; 19 minutes — p=0.011
Phase 2 N=48 Combination Chemotherapy in Treating Patients With Stage III or Stage IV Malignant Peripheral Nerve Sheath Tumors
Neurofibromatosis Type 1 · Sarcoma
Primary: Number of Participants With Response Rate (Complete Response and Partial Response) — 5; 4; 0; 0 Participants
Phase 2 N=20 Allogeneic Transplant in HIV Patients (BMT CTN 0903)
Leukemia · Lymphoma · HIV
Primary: Percentage of Participants With Non-Relapse Mortality — 0.0; 11.8; 18.3 percentage of participants
Phase 2 N=217 Intensive Motivational Interviewing for Methamphetamine Dependence
Methamphetamine Dependence
Primary: Methamphetamine Days of Abstinence : Proportion of Days Abstinent — .56; .55; .74; .74 proportion of days abstinent — p=.47